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Abstract
Background:  The hypothalamic-neurohypophysial system plays a fundamental role in the
maintenance of body fluid homeostasis by secreting arginine vasopressin (AVP) and oxytocin (OT)
in response to a variety of signals, including osmotic and nonosmotic stimuli. It is well established
that central cholinergic mechanisms are critical in the regulation of cardiovascular responses and
maintenance of body fluid homeostasis in adults. Our recent study demonstrated that
intracerebroventricular (i.c.v.) injection of carbachol elicited an increase of blood pressure in the
near-term ovine fetuses. However, in utero development of brain cholinergic mechanisms in the
regulation of the hypothalamic neuropeptides is largely unknown. This study investigated AVP and
OT neural activation in the fetal hypothalamus induced by central carbachol.
Results: Chronically prepared near-term ovine fetuses (0.9 gestation) received an i.c.v. carbachol
(3 μg/kg). Fetal blood samples were collected for AVP and OT assay, and brains were used for c-
fos mapping studies. I.c.v. carbachol significantly increased fetal plasma AVP and OT concentrations.
Intense FOS immunoreactivity (FOS-ir) was observed in the fetal supraoptic nuclei (SON) and
paraventricular nuclei (PVN) in the hypothalamus. Double labeling demonstrated that a number of
AVP- and OT-containing neurons in the fetal SON and PVN were expressing c-fos in response to
central carbachol.
Conclusion:  The results indicate that the central cholinergic mechanism is established and
functional in the regulation of the hypothalamic neuropeptides during the final trimester of
pregnancy. This provides evidence for a functional link between the development of central
cholinergic mechanisms and hypothalamic neuropeptide systems in the fetus.
Background
The central nervous system (CNS) contains extensive
cholinergic components [1], and central cholinergic path-
ways play an important role in the control of cardiovascu-
lar and body fluid homeostasis [2-6]. Carbachol, as a
cholinergic agonist elicits a variety of neurobiological and
physiological responses, including pressor responses,
thirst, natriuresis as well as secretion and release of
arginine vasopressin (AVP) in adult models [1,7-11].
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AVP and oxytocin (OT) are two major neuropeptides syn-
thesized and released by magnocellular neurosecretory
neurons in the hypothalamus. Both of them are involved
in vascular functions and hydromineral homeostasis [12].
A variety of signals, including the central cholinergic stim-
ulation, can cause release of AVP and OT in adults [13,14].
It is unknown however whether central cholinergic mech-
anisms have been developed in utero in the control of AVP
and OT systems in the fetal hypothalamus. Addressing
this question is important to both prenatal and postnatal
health problems. Despite this, our recent study has shown
that intracerebroventricular (i.c.v.) injection of carbachol
produces reliable pressor responses [15] accompanied by
a bradycardia in ovine fetuses at near-term. Both nicotine
and muscarinic receptors have been detected in the fetal
brain [16-20]. These results indicate that the central
cholinergic mechanism-mediated cardiovascular regula-
tion is functional in utero. In addition, studies from other
lines have shown that various signals, including angi-
otensin II, osmotic and hypovolemic stimulation, can
induce AVP secretion and release from the hypothalamus
and pituitary [21-26]. The evidence from these two lines
of research has independently proved that central cholin-
ergic systems have developed in the last third of gestation,
and the AVP system as a model of hypothalamic neu-
ropeptide pathways has matured enough in prenatal neu-
roendocrine regulation. However, a link or a functional
bridge between those two parts of studies has not been
established in fetuses. Thus, the present study was
designed to fill the gap and build an initial link between
these two lines of studies.
Based on available information, it is reasonable to
hypothesize that fetal brain cholinergic mechanisms-
mediated hypothalamic neuropeptide regulation is estab-
lished before birth. To test this hypothesis we used a
chronically prepared ovine fetal model. Under the
unstressful and unanaesthetised condition after surgical
recovery, ovine fetuses were tested following i.c.v. carba-
chol in utero. We determined the neural activity in the
hypothalamic nuclei, the fetal supraoptic nuclei (SON)
and paraventricular nuclei (PVN), under the condition of
presence of the central cholinergic signal. We also col-
lected fetal blood samples at real time during i.c.v. injec-
tion periods for measuring plasma AVP and OT levels.
Additionally, we characterized hypothalamic activated
cells induced by the central cholinergic signal. Informa-
tion gained is helpful to establish a functional "bridge"
between the functional development of the brain cholin-
ergic mechanism and the hypothalamic neuropeptide sys-
tems.
Results
Blood values
Histological analysis confirmed that all i.c.v. cannulae
were inserted into the fetal lateral vehicle. For both the
control and experimental animals, i.c.v. injection of car-
bachol (3 μg/kg) or vehicle had no effect on maternal or
fetal plasma osmolality, Na+, K+, and Cl- concentrations,
or arterial blood pH, PO2, PCO2, hemoglobin, and hema-
tocrit (all P > 0.05). All arterial values were within normal
ranges and were not different between the control and
experimental groups (all P > 0.05, Table 1).
Consistent with our previous studies [15], there was no
difference in maternal mean arterial pressure between
control and experimental groups (F8,1 = 0.12, P > 0.05).
However, i.c.v. injection of carbachol significantly
increased fetal mean arterial pressure (F8,1 = 15.42, P <
0.01). Fetal mean arterial pressure (F8,1 = 27.80, P < 0.01)
was increased and heart rate (F8,1 = 12.51, P < 0.01) was
decreased following central administration of carbachol
(data not shown).
Plasma AVP and OT assay
There was no significant difference in plasma AVP and OT
levels between the control and the experimental ewes to
i.c.v. injection (AVP: F8,1 = 0.37, OT: F8,1 = 0.23, both P >
0.05). However, the fetal AVP and OT concentrations were
significantly increased after i.c.v. carbachol administra-
tion (AVP: F8,1 = 73.60, OT: F8,1 = 58.61, P < 0.01). In the
control group, i.c.v. injection of the vehicle did not change
the maternal and fetal plasma AVP or OT levels. The i.c.v.
carbachol significantly increased fetal plasma AVP and OT
levels (AVP: F28,6 = 43.23; OT: F28,6 = 35.40, respectively,
both P < 0.01, the baseline period vs the period after i.c.v.
injection) (Figure 1 and 2). Fetal plasma AVP and OT
increased significantly within 15 minutes after i.c.v. carba-
chol, and the peak levels of plasma AVP and OT were
observed at 30 minutes (AVP: from base line level 3.5 ±
1.2 to 53.4 ± 9.5 pg/ml; OT: from base line level 35.6 ± 6.0
to 228.3 ± 23.2 pg/ml) after injection of carbachol. There
was no change in maternal plasma AVP and OT after i.c.v.
injection of carbachol into the fetus.
FOS-immunoreactivity and double labeling
In the control fetuses, there was no or few FOS-ir in the
basal forebrain structures. However, i.c.v. carbachol pro-
duced intense FOS-ir in the fetal forebrain, including the
SON and PVN in the hypothalamus (Figure 3 and 4).
There was a significant difference of FOS-ir in the SON
and PVN between the i.c.v. vehicle and the i.c.v. carbachol
injected fetuses (t = 11.2 and 8.9, respectively, both P <
0.01).
Double labeling showed that there was no FOS-ir in AVP-
containing and OT-containing cells in the brain of control
fetuses. However, co-localization of FOS-ir in many AVP
and OT neurons was detected in both sides of the SON
and PVN following i.c.v. carbachol in the fetal hypothala-
mus (Figure 5). Although many AVP and OT neurons
were co-localized with positive FOS-ir, there were someBMC Developmental Biology 2008, 8:95 http://www.biomedcentral.com/1471-213X/8/95
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AVP and OT cells not labeled with FOS-ir. There was no
difference in the total counting of AVP-ir and OT-ir in the
SON and PVN between the control and the treated fetuses
(all P > 0.05). Double labeling of FOS-ir and AVP-ir in the
SON was significantly higher in the carbachol-treated
fetuses than in the control animals (t = 6.78, P < 0.01).
82% of the AVP (+) neurons in the SON were FOS (+) in
the carbachol treated fetuses. However, very few of FOS
(+) cells in the SON (about 6%) were not AVP-containing
neurons. Also, double labeling of FOS-ir and OT-ir in the
PVN was significantly higher in the carbachol-treated
fetuses than in the control animals (t = 5.66, P < 0.01).
54% of the OT (+) neurons in the PVN were FOS (+) in the
carbachol treated fetuses, and only 8% of FOS (+) cells in
the PVN were not OT-containing neurons.
Discussion
The present study provides new insight that the central
cholinergic agonist causes AVP and OT release in the
ovine fetuses. The finding that c-fos expression was
induced in fetal AVP and OT neurons is the evidence that
the hypothalamic pathway is activated and cholinergic
mechanisms are functional in the control of fetal neu-
roendocrine function at 0.9 gestation.
Although there are evidence regarding to neuroendocrino-
logical responses induced by central cholinergic stimula-
tion in adults, to our knowledge, whether central
cholinergic mechanisms have developed in utero on the
control of the neuropeptide release from the fetal hypoth-
alamic-hypophysial system has been to date unknown. To
address this issue, two essential questions must be consid-
ered for the establishment of functional relationship
between cholinergic systems and hypothalamic neu-
ropeptide systems in the fetal brain. Firstly, cholinergic
binding sites must be intact and functional; and secondly,
the hypothalamic neuropeptide network must mature
enough in response to cholinergic signals. To answer the
first question, previous studies have demonstrated both
nicotinic and muscarinic receptors have developed in the
fetal brain [16-20]; our recent study has shown that i.c.v.
injection of carbachol produces reliable pressor responses
[15] in ovine fetuses at near-term, indicating that the cen-
tral cholinergic mechanisms-mediated cardiovascular reg-
ulation is functional in utero. To answer the second
question, by using neuroanatomical, immunochemical,
and molecular techniques, a variety of hypothalamic neu-
ropeptides such as corticotropin releasing hormone
(CRH), gonadotropin releasing hormone, growth hor-
mone releasing hormone, luteinizing hormone releasing
hormone, somatostatin, neurophysin, neuropeptide Y
were detected in the fetal hypothalamus [27-29]. For
example, hypothalamic CRH expression was increased at
the end of gestation [30], and the hypothalamic-pituitary-
adrenal (HPA) axis exists at late gestational period
[30,31]. Thus, the evidence from those two lines of
research has independently proven that central choliner-
gic receptor systems have well developed at least at late
gestation, and many neuropeptides pathways are matured
enough in prenatal neuroendocrine regulation. However,
Table 1: Fetal and maternal arterial values before and after intracerebroventricular carbachol injection into the fetal brain.
baseline 15 min 30 min 60 min 90 min
Fetus
pH 7.37 ± 0.01 7.36 ± 0.01 7.35 ± 0.01 7.35 ± 0.01 7.36 ± 0.01
PCO2 (mmHg) 47.6 ± 2.0 47.4 ± 1.8 48.3 ± 1.7 48.0 ± 1.6 48.6 ± 1.4
PO2 (mmHg) 21.2 ± 0.6 20.4 ± 1.5 20.6 ± 1.3 20.4 ± 1.4 20.5 ± 1.2
Hct (%) 25.1 ± 0.5 26.1 ± 1.0 26.5 ± 1.4 27.2 ± 1.5 26.9 ± 1.2
Hb (g/dL) 8.2 ± 0.4 8.6 ± 0.4 8.6 ± 0.6 8.5 ± 0.5 8.3 ± 0.4
Osmolality(mOsmol/kg) 302.6 ± 1.3 304.2 ± 1.7 303.8 ± 1.6 302.4 ± 1.6 303.4 ± 1.4
Na+ (mEq/L) 142.8 ± 0.9 142.5 ± 0.6 142.8 ± 0.7 142.6 ± 0.8 143.1 ± 0.6
K+ (mEq/L) 4.7 ± 0.2 4.6 ± 0.2 4.6 ± 0.1 4.6 ± 0.2 4.5 ± 0.2
Cl- (mEq/L) 109.7 ± 0.6 109.7 ± 0.7 109.3 ± 0.9 109.3 ± 0.8 109.4 ± 0.6
Maternal
pH 7.44 ± 0.05 7.44 ± 0.06 7.43 ± 0.05 7.44 ± 0.04 7.43 ± 0.07
PCO2 (mmHg) 33.7 ± 0.5 34.0 ± 3.3 34.5 ± 2.6 32.6 ± 0.9 34.8 ± 1.2
PO2 (mmHg) 113.4 ± 3.6 114.3 ± 2.6 114.0 ± 4.6 115.5 ± 3.2 117.5 ± 4.2
Hct (%) 28.3 ± 0.6 27.8 ± 1.0 27.1 ± 0.6 27.9 ± 0.9 27.6 ± 1.0
Hb (g/dL) 7.9 ± 0.4 8.1 ± 0.4 8.1 ± 0.6 7.7 ± 0.5 7.9 ± 0.4
Osmolality(mOsmol/kg) 304.2 ± 0.6 305.2 ± 1.2 306.6 ± 1.4 306.2 ± 1.5 305.6 ± 1.5
Na+ (mEq/L) 148.0 ± 0.8 147.9 ± 0.8 147.8 ± 06 147.6 ± 0.6 147.6 ± 0.6
K+ (mEq/L) 4.0 ± 0.1 4.0 ± 0.1 4.0 ± 0.1 4.1 ± 0.1 4.1 ± 0.1
Cl- (mEq/L) 113.4 ± 0.8 113.2 ± 0.7 113.1 ± 0.7 113.2 ± 0.9 113.5 ± 1.1
Upper panel, fetal arterial values; lower panel, maternal arterial values. Carbachol, 3 μg/kg. Values are mean ± SEM. Hct: hematocrit. Hb: 
hemoglobin.BMC Developmental Biology 2008, 8:95 http://www.biomedcentral.com/1471-213X/8/95
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The effect of i.c.v. carbachol on fetal (A) and maternal (B) plasma AVP concentration Figure 1
The effect of i.c.v. carbachol on fetal (A) and maternal (B) plasma AVP concentration. The dose of carbachol, 3 
μg/kg; 0 min: time for i.c.v. injection. *, P < 0.01 compared with the baseline level. AVP: arginine vasopressin.
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The effect of i.c.v. carbachol on fetal (A) and maternal (B) plasma OT concentration Figure 2
The effect of i.c.v. carbachol on fetal (A) and maternal (B) plasma OT concentration. The dose of carbachol, 3 μg/
kg; 0 min: time for i.c.v. injection. *, P < 0.01 compared with the baseline level. OT: oxytocin.
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a link or a functional bridge between those two parts of
studies has so far not been established. In light of this, the
new findings from the present study may fill this gap.
AVP and OT are two main neuropeptides synthesized by
magnocellular neurosecretory neurons in the SON and
PVN in the hypothalamus. Previous studies in fetal mod-
els have shown that the hypothalamic AVP and OT sys-
tems are relatively intact before birth [21-23,32], and
various signals, including angiotensin II, osmotic and
hypovolemic stimulation, can induce AVP secretion from
the fetal hypothalamus [21-26]. Thus, it should not be
strange to use the AVP and OT system as a model to study
hypothalamic neuropeptides in fetuses.
In addition to the main physiological effect of antidiure-
sis, the peripheral AVP also participate in the vasoconstric-
tion and pressor responses in both adults and fetuses
[24,33]. In the present study, we demonstrated that i.c.v.
injection of cholinergic agonist carbachol induced a
marked increase of fetal plasma AVP concentrations with-
out influence on maternal AVP levels. The fetal AVP in cir-
culation reached the peak in 30 mins which is about 15
fold of the baseline level. Associated with the plasma AVP
elevation, the fetal arterial blood pressure also increases
significantly. Whether increased AVP levels contributed to
pressor responses still needs further studies.
In comparison to studies on fetal AVP, the present study
was the first experiment using central injection approach
in utero to investigate the hypothalamic OT system. OT is
an important hormone not only inducing sexual and
maternal behavior, but also be involved in vascular and
cardiac relaxation and hydromineral homeostasis [34-
36]. Previous studies indicated that fetal plasma OT con-
centrations changed in sheep with the gestation age. At
The effect i.c.v. injection of carbachol on FOS-ir in the fetal hypothalamus Figure 3
The effect i.c.v. injection of carbachol on FOS-ir in the fetal hypothalamus. The dose of carbachol, 3 μg/kg; SON: 
the supraoptic nuclei; PVN: the paraventricular nuclei. *, P < 0.01 compared with the control level.
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the last third of gestation, the fetal plasma OT levels were
usually higher than maternal OT levels [37]. Our results
showed that the baseline level of fetal plasma OT level is
35.6 ± 6.0 pg/ml, which is significantly higher than the
maternal levels (20.0 ± 5.8 pg/ml) at near-term gestation.
After i.c.v. injection of carbachol, fetal plasma OT
increased about six times of the baseline level and reached
the maximum within 30 mins. The increase of OT lasted
for more than 90 mins. Similar to AVP, the lack of change
of the maternal plasma OT suggests that the increased
fetal plasma OT is released from its own nerurohypophy-
sis in response to central carbachol and fetal OT seems not
pass the placental barrier to the maternal side. Notably,
the increased fetal plasma OT by i.c.v. carbachol is less
than the increased of AVP compared to the baseline,
which is quite different from adults in the same neuropep-
tide responses [13]. Lauand et al reported that under the
same condition of carbachol stimulation, the fold of
increased AVP and OT was similar [13]. While in our
fetuses, it seems the AVP neurons had a lower response
threshold than OT neurons to cholinergic stimulation.
Previous studies on the initiation of parturition show that
fetal OT may play an important role in signal processing
of labor. Fetal OT may initiate or accelerate the course of
labor, while fetal AVP plays a role in the adaptation to
stress-caused by the birth process-by redistribution of the
fetal blood flow [38]. OT has been suggested to be
involved in the regulation of adrenocorticotropic hor-
mone (ACTH) secretion in fetal sheep in late gestation
[32], and the latter plays an important role in the onset of
spontaneous birth. With permanent bilateral PVN lesions
FOS-ir induced by i.c.v. carbachol in the fetal SON and PVN Figure 4
FOS-ir induced by i.c.v. carbachol in the fetal SON and PVN. SON (upper panel) and PVN (bottom panel). A and C: 
the animal treated with i.c.v. vehicle; B and D: the animal injected with i.c.v. carbachol (3 μg/kg). 3V: the third ventricle. Scale 
bar = 200 μm.
A  B
C D
3V 3VBMC Developmental Biology 2008, 8:95 http://www.biomedcentral.com/1471-213X/8/95
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FOS-ir and AVP-ir (or OT-ir) in the SON and PVN following i.c.v. carbachol Figure 5
FOS-ir and AVP-ir (or OT-ir) in the SON and PVN following i.c.v. carbachol. A: double labeling of FOS-ir and AVP-
ir in the SON. B: double labeling of FOS-ir and OT-ir in the PVN. Solid arrows indicate co-localization of FOS-ir and AVP-ir (or 
OT-ir). Open arrows indicate AVP-ir (or OT-ir) positive cells without FOS-ir. Dash arrows indicate positive FOS-ir outside of 
AVP- (or OT-ir) containing cells. Scale bar = 10 μm.
B
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placed at 106–110 or 118–122 days of gestation, the most
apparent physiological change is that the fetal sheep fails
to deliver [39,40]. These observations demonstrate that
the fetal brain structure, PVN, is necessary for parturition
to occur. The PVN is not only abundant of CRH neurons
but also the main source for OT synthesis. Therefore, a
sharp increase of OT in the fetal body could be viewed as
a critical signal for giving birth, and this hormone contrib-
utes partially to initiation of labor. We speculate that cer-
tain protective mechanisms may exist in premature fetuses
to prevent dramatically increasing of OT to initiate prema-
ture labor. This could be one of reasons why the released
OT is relatively less than AVP under the same condition in
the fetus compared to that in adults, indicting that fetal
OT neurons showed a lower responsive ability in secre-
tion or release of OT into the circulation from the fetal
brain. However, additional studies are needed for to clar-
ify this further.
In light of this, one important significance of the
increased OT by the central cholinergic signal in the
present study is linked to clinical problem-premature
birth. If fetal central cholinergic mechanism is over acti-
vated by any factor at the wrong time (before term), it is
very likely to induce premature labor due to a significant
increase of fetal plasma OT levels. It is clear that many
environmental factors or maternal conditions such as
smoking may increase cholinergic activity in the fetal
CNS. Therefore, those environmental and maternal fac-
tors could also subsequently produce a higher level of OT
in utero according to the new finding in the present study.
Therefore, to prevent of premature birth, one may need to
pay attention to factors that can increase central choliner-
gic activity in the fetal brain.
Previous studies in adult animals showed that hyperos-
molality is a potent stimulus in the control of AVP and OT
secretion [41-43]. A significant correlation has been
found between plasma osmolality and AVP and OT con-
centrations following intraperitoneal or intravenous
administration of hypertonic NaCl [25,44]. However, in
the present study, the fetal physiological status remained
stable after surgical recovery and under the condition of
i.c.v. injection of carbachol as arterial values (pH, PCO2,
PO2, and plasma electrolytes) were not changed. Conse-
quently, unchanged fetal plasma osmolality and sodium
levels make it unlikely that the central carbachol induced
release of fetal AVP and OT was due to osmotic mecha-
nisms.
In addition to hyperosmolar stimulus, hypovolemia and
hypotension also can enhance the release of AVP and OT
[35,45]. However, in the present study, fetal blood hema-
tocrit and hemoglobin were not affected by the central
carbachol, indicating unchanged fluid volume. Further-
more, if there was decrease of extracellular volume, the
arterial blood pressure would be subsequently lowered.
However, the results of pronounced pressor responses in
the present as well as previous study [15] after the i.c.v.
carbachol do not support the possibility that volume
mechanisms may contribute to AVP and OT release by
central cholinergic stimulation in utero.
Hypoxemia is also reported as being a potent stimulus of
fetal AVP secretion [46,47]. The fetal arterial PO2 is stable
before and after i.c.v. carbachol, therefore can excluding
this possibility.
A more likely explanation for the elevation of the fetal
plasma AVP and OT is the facilitation by central choliner-
gic stimuli per se. Central carbachol activates neural path-
ways in the brain. The significant enhancement of activity
of fetal AVP and OT neurons suggests that central cholin-
ergic mechanisms is functional in the control of the
hypothalamic neuropeptide systems. Combining the
results of plasma AVP and OT changes following i.c.v. car-
bachol, we can get at least three preliminary conclusions:
(1) the fetal hypothalamic OT system is functional intact
at least at near-term; (2) central cholinergic signals play a
role in the control of release of both AVP and OT from the
fetal brain; and (3) the network or bridge between central
cholinergic signals and the hypothalamic neuropeptide
systems have been developed at 0.9 gestation in utero.
Several lines of evidence showed that multiple sites in the
CNS play a role in cholinergically mediated neuroendo-
crine regulation, and that regulation by centrally adminis-
tered cholinergic agonists are site-specific. To determine
central actions of carbachol in the fetal hypothalamus, a
c-fos mapping was employed in this study. FOS protein
immunoreactivity has been widely used as a marker of
neuronal activation [48,49] following i.c.v. injection of
neuroactive substances including carbachol [1,13]. In the
present study, a number of neurons or cells were activated
with the expression of c-fos in both PVN and SON in the
fetal hypothalamus following i.c.v. carbachol. A question
was then raised: what kind of neurons or neurosecretary
cells in the fetal hypothalamus responded to the choliner-
gic signal? In addressing this question, we used double
labeling experiments to characterize the hypothalamic
activated cells. Notably, three phenomena were observed:
(1) co-localization of FOS-ir and AVP-ir or OT-ir; (2) AVP-
ir or OT-ir positive while FOS-ir negative; (3) FOS-ir pos-
itive while AVP-ir and OT-ir negative. The first phenome-
non demonstrates that many AVP- or OT-containing
neurons were activated. Regardless of whether the AVP
and OT neurons in the fetal hypothalamus were activated
by carbachol directly or via other pathways indirectly fol-BMC Developmental Biology 2008, 8:95 http://www.biomedcentral.com/1471-213X/8/95
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lowing the i.c.v. carbachol, the c-fos expression induced in
these nuclei is evidence that central AVP and OT systems
are relatively intact and sufficiently functional to choliner-
gic stimulation at near-term. The elevation of plasma AVP
and OT concentrations is further support for the central
neuron activation. The second phenomenon indicates
that some of the AVP and OT neurons do not express FOS-
ir following carbachol stimulation. Although numerous
evidence from previous studies support that FOS acts as a
marker of neuron activation, caution should be taken
when negative expression of c-fos appears in experiments.
There could be two possibilities, one was that these mag-
nocellular neurons were not activated; the other was they
might be activated but did not express FOS protein. The
third phenomenon suggests that c-fos located in other
activated cells that were neurons other than vasopressin-
ergic and oxytocinergic cells.
Although we mainly focused on the fetal hypothalamus in
this study, our previous study [15] showed that the similar
i.c.v. cholinergic stimulation also can induce cellular acti-
vation in the fetal anterior third ventricle (AV3V) region
(including the median preoptic nucleus and organum vas-
culosum of the lamina terminalis) in the forebrain, and
the areas (such as the area postrema, lateral parabrachial
nucleus, nucleus tractus solitary, and rostral ventrolateral
medulla) in the hindbrain of the ovine fetus. Those cen-
tral structures have rich connections with the hypotha-
lamic PVN and SON in adults. Further studies are required
to elucidate the activation of AVP and OT neurons in the
present study was due to direct, or indirect, or both routes
by central carbachol. The results gained will provide addi-
tional information on the development of central path-
ways related to cholinergic signals.
Conclusion
The present study demonstrated, for the first time, that
i.c.v. carbachol could induce fetal AVP and OT release at
0.9 gestation, indicating functional maturation of the cen-
tral cholinergic mechanism-mediated neuroendocrine
secretion in the fetal hypothalamus. The hormonal
responses are associated with activation of AVP and OT
neurons in the fetal SON and PVN, confirming that the
hypothalamic-neurohypophysial system has been well
developed and plays important roles in the cholinergic-
mediated neuroendocrine regulation before birth. This
novel and important data increases our understanding of
the functional development of brain cholinergic mecha-
nisms in the control of neuropeptide in utero. The present
data not only provide evidence of the functional develop-
mental picture of brain hypothalamic-neurohypophysial
systems in response to cholinergic signals at 0.9 gestation,
but also offers a useful experimental model in study of the
development of hypothalamic pathways in respond to
central neuroactive substances in utero.
Methods
Animals and surgical preparation
Time-dated pregnant ewes with singleton fetuses (gesta-
tional age 130 ± 3, term ~145 days) were used. The ovine
were housed indoors in individual steel study cages and
acclimated to a 12:12-h light-dark cycle. Both food and
water were provided ad libitum, except for the last 24 h
before surgery, when food was withheld. All protocols in
this study were approved by Soochow University School
of Medicine Animal Care Committee.
Surgery was performed under strict aseptic conditions.
Anesthesia was induced by an intramuscular injection of
ketamine hydrochloride (20 mg/kg) plus atropine sulfate
(50 μg/kg) and was maintained by maternal endotracheal
ventilation with 1 L/min oxygen and 3% isoflurane. Poly-
ethylene catheters (ID = 1.8 mm, OD = 2.3 mm) were
inserted into a maternal femoral vein and artery and
advanced into the inferior cava and abdominal aorta,
respectively. The uterus was exposed by a midline abdom-
inal incision, and a small hysterotomy was performed to
provide access to fetal hindlimbs. Polyethylene catheters
(ID = 1.0 mm, OD = 1.8 mm) were inserted into the fem-
oral vein and artery. After closure of this initial uterine
incision, a second uterine incision was made over the fetal
head. A midline incision was made to expose the skull and
an intracranial cannula (18 gauge) was placed in the fetal
lateral ventricle and held in place with dental cement. The
coordinates for cannula placement were: anterior-poste-
rior: +0.1 cm in t front of the bregma; medial-lateral: 0.8
cm from the middle line; and ventral: 1.8 cm below the
dura. Patency of the catheter at insertion was assessed by
free flow of cerebrospinal fluid via gravity drainage (the
placement of cannula was ultimately verified by histolog-
ical analysis following kill of each animal). An intrauter-
ine catheter was inserted for measuring amniotic fluid
pressure. The uterine incisions were closed in layers. All
catheters were passed through a subcutaneous tunnel and
exteriorized through a small incision on the ewe's flank.
Catheters were kept in a cloth pouch attached to the ewe's
flank and filled with heparinized saline.
Five days of postoperative recovery were allowed before
experimental studies. Antibiotics were administered intra-
venously twice daily to the ewe (70 mg gentamicin and 1
g oxacillin) and to the fetus (8 mg gentamicin and 30 mg
oxacillin) during the first 2–3 days postsurgery.
Experimental protocol
All experiments were performed on conscious animals
standing in their holding cages, with food and water pro-
vided ad libitum. Studies began with a baseline period (-
60 to 0 minutes) followed by experimental period (0 to
120 minutes) in two groups (control: n = 5; experimental:
n = 5). Beginning at time 0, carbachol (3 μg/kg, Sigma) inBMC Developmental Biology 2008, 8:95 http://www.biomedcentral.com/1471-213X/8/95
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isotonic saline (1 ml) was injected i.c.v. into the fetus over
5 minutes. Drug doses were based on estimated fetal body
weight [50]. To the control animals, isotonic saline (vehi-
cle) was injected. Throughout the basal and experimental
periods, maternal and fetal arterial blood was withdrawn
at timed intervals for measurement of pH, blood gases,
hematocrit, plasma electrolyte composition, osmolality,
AVP and OT concentrations. Fetal blood samples were
replaced with an equivalent volume of heparinized mater-
nal blood withdrawn before the study. Blood PO2, PCO2,
and pH were measured at 39°C with a Nova analyzer sys-
tem (AD Instruments, Australia). Plasma and urinary
osmolality was measured by freezing-point depression on
an Advanced Digimatic osmometer (Advanced Instru-
ments, Needham Heights, MA).
Throughout the study, maternal and fetal systolic and
diastolic pressure, amniotic fluid pressure, and heart rate
were monitored. The fetal mean arterial pressure (MAP)
was corrected for amniotic cavity pressure.
Hormone Experiments
The maternal and fetal blood samples were collected into
iced tubes containing lithium heparin during the baseline
and the experimental periods. Blood samples for AVP and
OT assays were centrifuged immediately. The plasma was
then stored at -20°C before radioimmunoassay (RIA).
Plasma AVP and OT concentrations were measured using
Sep-Pak C18 cartridge extraction. Samples for AVP and OT
extraction were acidified with 1N HCl and extracted. Acid-
ified plasma samples were added slowly to the columns,
and the columns were washed with 0.1% trifluoroacetic
acid. The absorbed AVP and OT were eluted with 50%
methanol and 0.1% TFA, and the eluates were dried in a
Speed-Vac concentrator. The assay sensitivity was 1.2 pg
for AVP/tube and 1.6 pg for OT/tube. The intra- and inter-
assay coefficients of variations were, respectively, 7 and
9% for AVP, and 8 and 12% for OT, respectively. AVP and
OT recoveries average 70% in our laboratory. All plasma
samples were processed together.
Immunohistochemistry and double labeling experiments
At the conclusion of the study, the animals were anesthe-
tized and ventilated with a mixture of isoflurane and oxy-
gen as described. A middle abdominal incision was made
and the fetal head and neck were exposed. A 16-gauge nee-
dle was inserted into the fetal carotid artery for perfusion
with 0.1 M phosphate buffered saline followed by 4%
paraformaldehyde in 0.1 M phosphate buffer under
anesthesia. The perfusion period was about 5–7 min, and
the fetus was decapitated during perfusion. The brain was
removed immediately following perfusion. Post-fixation
was performed in the paraformaldehyde solution for 12 h,
after which the brain was placed in 20% sucrose over-
night. Twenty-micrometer coronal sections were cut
through the fetal brain on a cryostat. Every other sections
of the SON and PVN in the hypothalamus were used for
c-fos immunoreactivity (FOS-ir) staining using the avidin-
biotin-peroxidase technique. The tissue sections were
incubated on a gentle shaker overnight at 4°C in the pri-
mary antibody (1:15,000, Santa Cruz Biotechnology,
Santa Cruz, CA). The polyclone FOS primary antibody has
been raised from rabbits against the N-terminal sequence
of the FOS protein. The sections were further incubated in
a goat anti-rabbit serum (1:400) for 1 h and then proc-
essed using the Vectastain ABC kit for 1 h (Vector Labs,
Burlingame, CA) at room temperature. Immediately fol-
lowing FOS immunostaining, tissue sections were used
for double immunostaining by using AVP or OT antibody.
The method of double labeling was the same as reported
[25]. The sections were then treated with 1 mg/ml diami-
nobenzidine tetrahydrochloride (Sigma-Aldrich, St.
Louis, MO) (0.02% hydrogen peroxide). All sections were
mounted on slides, dehydrated in alcohol, and then cover
slipped.
Data Analysis
The number of FOS-ir positive cells in the brain was eval-
uated in a qualitative and blinded manner as reported
[51]. The number of FOS-ir positive cells in the all stained
sections for the SON and PVN was counted. A repeated
measures ANOVA was used to determine differences over
time and effects of the treatments. Comparison before and
after the treatments was determined with one-way
ANOVA followed by the Tukey post hoc test or Student's t-
test. All data were expressed as mean ± SEM. Statistic sig-
nificance was accepted at P < 0.05.
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